When the Justice Department announced it was bringing criminal charges against two former executives of a pharmaceuticals company, alleging a conspiracy to fix prices on generic drugs, we said that this was likely just the tip of the legal iceberg. Today, the industry ran smack into that iceberg — in the form of a lawsuit filed by twenty states against six different drug companies, including notables like Teva and Mylan. [More]
teva
Mylan To Start Selling $300 Generic EpiPen Pack Next Month
By 11.10.16
Under pressure to reduce the price of its expensive EpiPen emergency allergy treatment, drugmaker Mylan said in August that it would be introducing a generic version of the drug at half the retail price. Now it looks like the less-costly epinephrine auto-injector will be hitting the market after Thanksgiving.
EpiPen Competitor Auvi-Q Relaunching Next Year
By 10.26.16 — Updated: 10.31.16
Almost exactly a year after pharmaceutical maker Sanofi recalled nearly 500,000 epinephrine injectors after finding they might not provide the correct dosage to patients, the product is gearing up for a comeback, potentially creating a less expensive competitor to the highly scrutinized EpiPen. [More]
Pharmaceutical Companies Accused Of Colluding To Delay Generic Version Of Popular Cholesterol Drug
By 10.10.16
If you’ve got a patent-protected drug that’s bringing in more than $1 billion a year in sales, you stand to lose a significant chunk of that revenue when the patent expires and lower-cost generic versions come on the market. A California prosecutor alleges that a number of drug companies illegally colluded in a nearly decade-long “pay-for-delay” deal intended to prevent the release of a cheaper competitor to a popular cholesterol drug. [More]
CEO Of EpiPen Maker Mylan To Face Congressional Hearing Next Week
By 9.14.16
In recent weeks, members of both the House and Senate have raised questions about the soaring price of — and potential antitrust concerns surrounding — emergency allergy treatment EpiPen. A congressional committee confirmed this morning that it will soon hold a hearing on the issue, and that Heather Bresch, CEO of EpiPen maker Mylan, has been called to testify. [More]
Go Hiking In Style With These Teva Stiletto Heels
By 11.29.10
Teva sandals are no longer for granola-crunching outdoors types. Now the fashion-conscious adventurer can go straight from the rugged rocks to the black-tie fundraiser without missing a beat. [More]
Teva Pharmaceuticals: The Ubiquitous Company You've Never Heard Of
By 5.12.10
Generic prescription drugs are just that: generic. Most patients don’t think much about who actually manufactures them. It’s pretty likely, however, that you have something in your medicine cabinet manufactured by Israel’s Teva Pharmaceutical Industries Ltd. A profile of the company in this past weekend’s New York Times is fascinating. Most interesting of all: while the company is sensibly frugal enough to make Captain Moneycat purr, they refuse to move manufacturing to China or India, as many of their competitors have. [More]
